Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bruce Evan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Bruce Johnson and Hiroto Hatabu.
Connection Strength

1.624
  1. Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76.
    View in: PubMed
    Score: 0.207
  2. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004.
    View in: PubMed
    Score: 0.160
  3. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8.
    View in: PubMed
    Score: 0.144
  4. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68.
    View in: PubMed
    Score: 0.144
  5. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013 Jul; 201(1):W64-71.
    View in: PubMed
    Score: 0.143
  6. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8.
    View in: PubMed
    Score: 0.138
  7. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012 Jun 29; 12:225-35.
    View in: PubMed
    Score: 0.133
  8. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
    View in: PubMed
    Score: 0.119
  9. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107.
    View in: PubMed
    Score: 0.057
  10. Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210.
    View in: PubMed
    Score: 0.056
  11. Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131.
    View in: PubMed
    Score: 0.053
  12. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754.
    View in: PubMed
    Score: 0.053
  13. Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. Eur J Radiol. 2017 Mar; 88:15-20.
    View in: PubMed
    Score: 0.045
  14. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36.
    View in: PubMed
    Score: 0.043
  15. State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014 Apr; 271(1):6-27.
    View in: PubMed
    Score: 0.038
  16. Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov; 78(2):161-6.
    View in: PubMed
    Score: 0.034
  17. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
    View in: PubMed
    Score: 0.030
  18. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.